ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Ticagrelor and Aspirin or Aspirin Alone After Coronary Surgery for Acute Coronary Syndrome

Thursday, September 4, 2025

Submitted by

Joel Dunning

Source

Source Name: The New England Journal of Medicine

Source URL: https://www.nejm.org/doi/full/10.1056/NEJMoa2508026

Author(s)

Anders Jeppsson, Stefan James, Christian H. Moller, Carl Johan Malm, Magnus Dalén, Farkas Vanky, Ivy Susanne Modrau, Karl Andersen, Vesa Anttila, Gennady V. Atroshchenko, Mikael Barbu, Mats Dreifaldt, Ali Imad El-Akkawi, Örjan Friberg, Tomas Gudbjartsson, Jarmo Gunn, Rune Haaverstad, Jari Halonen, Emma C. Hansson, Jonas Holm, Annastiina Husso, Tatu Juvonen, Øyvind Jakobsen, Lena Jideus, Emilia Johannesson, Anna Jonsson Holmdahl, Kristjan Jonsson, Solveig Moss Kolseth, Lytfi Krasniqi, Tuomas Mäkelä, Ari Mennander, Lars-Erik Mohagen Krogstad, Sulman Rafiq, Peter Raivio, Lars Riber, Aminah Tahir, Carl Thorsen, Theis Tønnessen, Alexander Wahba, Igor Zindovic, Aldina Pivodic, Susanne J. Nielsen, David Erlinge, Joakim Alfredsson, Ulrik Sartipy

This article examines the effects of adding ticagrelor to aspirin in patients undergoing coronary artery bypass grafting (CABG) for acute coronary syndrome. The randomized trial involved 2,201 patients and found no significant difference in the primary outcome of death, myocardial infarction, stroke, or repeat coronary revascularization between the ticagrelor-plus-aspirin group and the aspirin-alone group after one year. However, the ticagrelor-plus-aspirin group had a higher incidence of major bleeding, suggesting the need for careful consideration regarding dual antiplatelet therapy in this population.